175 related articles for article (PubMed ID: 31225597)
1. Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
Gulati R; Morgan TM; A'mar T; Psutka SP; Tosoian JJ; Etzioni R
J Natl Cancer Inst; 2020 Apr; 112(4):384-390. PubMed ID: 31225597
[TBL] [Abstract][Full Text] [Related]
2. Lifetime Benefits and Harms of Prostate-Specific Antigen-Based Risk-Stratified Screening for Prostate Cancer.
Heijnsdijk EAM; Gulati R; Tsodikov A; Lange JM; Mariotto AB; Vickers AJ; Carlsson SV; Etzioni R
J Natl Cancer Inst; 2020 Oct; 112(10):1013-1020. PubMed ID: 32067047
[TBL] [Abstract][Full Text] [Related]
3. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
[TBL] [Abstract][Full Text] [Related]
6. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
7. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
8. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
9. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
10. Expected population impacts of discontinued prostate-specific antigen screening.
Gulati R; Tsodikov A; Etzioni R; Hunter-Merrill RA; Gore JL; Mariotto AB; Cooperberg MR
Cancer; 2014 Nov; 120(22):3519-26. PubMed ID: 25065910
[TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
Roobol MJ; Kranse R; Bangma CH; van Leenders AG; Blijenberg BG; van Schaik RH; Kirkels WJ; Otto SJ; van der Kwast TH; de Koning HJ; Schröder FH;
Eur Urol; 2013 Oct; 64(4):530-9. PubMed ID: 23759326
[TBL] [Abstract][Full Text] [Related]
12. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
14. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.
Parekh DJ; Punnen S; Sjoberg DD; Asroff SW; Bailen JL; Cochran JS; Concepcion R; David RD; Deck KB; Dumbadze I; Gambla M; Grable MS; Henderson RJ; Karsh L; Krisch EB; Langford TD; Lin DW; McGee SM; Munoz JJ; Pieczonka CM; Rieger-Christ K; Saltzstein DR; Scott JW; Shore ND; Sieber PR; Waldmann TM; Wolk FN; Zappala SM
Eur Urol; 2015 Sep; 68(3):464-70. PubMed ID: 25454615
[TBL] [Abstract][Full Text] [Related]
15. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
[TBL] [Abstract][Full Text] [Related]
16. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
17. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
18. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.
Bokhorst LP; Bangma CH; van Leenders GJ; Lous JJ; Moss SM; Schröder FH; Roobol MJ
Eur Urol; 2014 Feb; 65(2):329-36. PubMed ID: 23954085
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
